Calidi Biotherapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4475 Executive Dr Ste 200, San Diego, Ca...Phone Number
(858) 794-9600Website
www.calidibio.comRevenue
-Stock Symbol
CLDIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Calidi Biotherapeutics is headquartered in San Diego, California.Explore more
Calidi Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Calidi Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Calidi Biotherapeutics recently announced quarterly report
Check out if Calidi Biotherapeutics is spiking on competitors!
Click to see if Calidi Biotherapeutics had a recent Job posting/layoffs
Calidi Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Calidi Biotherapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Calidi Biotherapeutics
Product Launch: Get notified when Calidi Biotherapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Calidi Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Calidi Biotherapeutics
Compare insights from companies similar to Calidi Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Calidi Biotherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Calidi Biotherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Calidi Biotherapeutics.
Calidi Biotherapeutics financials insights
Gather financial insights about Calidi Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2023
Series B
$25M
Calidi Biotherapeutics Tech Stack
A closer look at the technologies used by Calidi Biotherapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Funding
, a clinical‐stage immuno-oncology company, has secured an undisclosed amount of Series A funding. Backers included Won & Partners and Greentable Co., Ltd.
Funding
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Calidi Biotherapeutics News & Media
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on July 23, 2026, at the American Association for Cancer Research Drug Discovery and Development (AACR D3) Conference in Boston, MA. The Company presented new data on its CLD-401 program that it expects to enter the clinic in the first quarterCalidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today recapped 2026 successes to date and provided an update on the Company’s upcoming milestones.Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medicine, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-16 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on JulyCalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company’s Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Ms. Gurrola for the purchase of 100,000 shares with an exercise price of $0.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Calidi Biotherapeutics
Sign Up For FreeTo access detailed company insights
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in mult... Read More
